NGS is making waves as it translates from research to the clinic.!--h2>
Enal Razvi, Ph.D.
We provide an update of the trajectory of the migration of next-generation sequencing (NGS) from the research space toward clinical application and clinical impact in this GEN report as part of our continuing coverage of the evolution of the NGS industry landscape.
Highlights of this report:
There are defined research offerings from several vendors for NGS front-end sample processing and preparation.
Many of these kit-formatted products are available and are designed for research use (RUO).
There is a defined clinical translation of NGS that is taking place, and one of the key drivers of this translation toward the clinic is the approval of the Illumina MiSeqDx platform by the FDA.
Indeed today there are a number of LDTs deploying NGS with specific gene panels—primarily focusing on oncology—but expanding out into other disease classes also.
The development of ecosystems of researchers developing NGS-based applications will propel this translation of NGS from research to clinic.
Enal Razvi, Ph.D., conducted his doctoral work on viral immunology and subsequent to receiving his Ph.D. went on to the Rockefeller University in New York to serve as Aaron Diamond Post-doctoral fellow under Professor Ralph Steinman [Nobel Prize Winner in 2011 for his discovery of dendritic cells in the early-70s with Zanvil Cohn]. Subsequently, Dr. Razvi completed his research fellowship at Harvard Medical School. For the last two decades Dr. Razvi has worked with small and large companies and consulted for more than 100 clients worldwide. He currently serves as Biotechnology Analyst and Managing Director of SelectBio U.S. He can be reached at email@example.com.